AR078224A1 - Composicon para el tratamiento del cancer de prostata - Google Patents
Composicon para el tratamiento del cancer de prostataInfo
- Publication number
- AR078224A1 AR078224A1 ARP100101489A ARP100101489A AR078224A1 AR 078224 A1 AR078224 A1 AR 078224A1 AR P100101489 A ARP100101489 A AR P100101489A AR P100101489 A ARP100101489 A AR P100101489A AR 078224 A1 AR078224 A1 AR 078224A1
- Authority
- AR
- Argentina
- Prior art keywords
- degarelix
- solvent
- composition
- treatment
- prostate cancer
- Prior art date
Links
- 206010060862 Prostate cancer Diseases 0.000 title abstract 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 title abstract 2
- 108010052004 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide Proteins 0.000 abstract 8
- MEUCPCLKGZSHTA-XYAYPHGZSA-N degarelix Chemical compound C([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CC=1C=CC(NC(=O)[C@H]2NC(=O)NC(=O)C2)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(NC(N)=O)C=C1 MEUCPCLKGZSHTA-XYAYPHGZSA-N 0.000 abstract 8
- 229960002272 degarelix Drugs 0.000 abstract 8
- 239000002904 solvent Substances 0.000 abstract 4
- 238000012423 maintenance Methods 0.000 abstract 3
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Reivindicacion 1: Una composicion que comprende degarelix o una sal farmacéuticamente aceptable del mismo para el tratamiento del cáncer de prostata, en donde la composicion comprende un liofilisato de degarelix y un excipiente disuelto en un solvente, y es administrada a un paciente en una dosis inicial de entre 200 y 300 mg de degarelix a una concentracion de entre 20 y 80 mg de degarelix por mL de solvente; seguido 14 - 56 días luego de la dosis inicial por una dosis de mantenimiento de entre 320 y 550 mg de degarelix a una concentracion de entre 50 y 80 mg de degarelix por mL de solvente; (opcionalmente) seguido por una o más dosis adicionales de mantenimiento(s) de entre 320 y 550 mg de degarelix a una concentracion de entre 50 y 80 mg de degarelix por mL de solvente administrada con un intervalo de 56 días a 112 días entre cada dosis de mantenimiento.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09251242 | 2009-05-01 | ||
| US18781909P | 2009-06-17 | 2009-06-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR078224A1 true AR078224A1 (es) | 2011-10-26 |
Family
ID=41066059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100101489A AR078224A1 (es) | 2009-05-01 | 2010-04-30 | Composicon para el tratamiento del cancer de prostata |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8722088B2 (es) |
| EP (1) | EP2424503B1 (es) |
| JP (6) | JP5973909B2 (es) |
| KR (1) | KR101795643B1 (es) |
| CN (2) | CN102421414A (es) |
| AR (1) | AR078224A1 (es) |
| AU (1) | AU2010243273B2 (es) |
| BR (1) | BRPI1010874A8 (es) |
| CA (1) | CA2759888A1 (es) |
| ES (1) | ES2641767T3 (es) |
| IL (1) | IL215772A (es) |
| MX (1) | MX2011011431A (es) |
| NZ (1) | NZ595767A (es) |
| RU (1) | RU2536245C2 (es) |
| SA (1) | SA110310340B1 (es) |
| TW (2) | TWI583391B (es) |
| WO (1) | WO2010125468A1 (es) |
| ZA (1) | ZA201107879B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0117057D0 (en) * | 2001-07-12 | 2001-09-05 | Ferring Bv | Pharmaceutical composition |
| TWI539959B (zh) | 2008-02-11 | 2016-07-01 | 菲瑞茵國際中心股份有限公司 | 治療轉移階段攝護腺癌的方法 |
| AU2010243273B2 (en) * | 2009-05-01 | 2016-06-16 | Ferring B.V. | Composition for the treatment of prostate cancer |
| US20110039787A1 (en) * | 2009-07-06 | 2011-02-17 | Ferring International Center S.A. | Compositions, kits and methods for treating benign prostate hyperplasia |
| ES2623127T3 (es) | 2010-02-01 | 2017-07-10 | Mikrobex | Bacterioterapia para la colitis por Clostridium difficile |
| EP2447276A1 (en) | 2010-10-27 | 2012-05-02 | Ferring B.V. | Process for the manufacture of Degarelix and its intermediates |
| LT2632934T (lt) | 2010-10-27 | 2017-01-10 | Ferring B.V. | Degarelikso ir jo tarpinių darinių gamybos būdas |
| JO3755B1 (ar) | 2011-01-26 | 2021-01-31 | Ferring Bv | تركيبات تستوستيرون |
| CN102204889B (zh) * | 2011-05-23 | 2013-09-18 | 蚌埠丰原涂山制药有限公司 | 一种醋酸地加瑞克冻干粉针剂及其制备方法 |
| PL4512389T1 (pl) * | 2012-06-01 | 2025-09-01 | Ferring B.V. | Produkt leczniczy degareliksu |
| JP6330032B2 (ja) | 2013-06-05 | 2018-05-23 | レビオティクス インコーポレイテッドＲｅｂｉｏｔｉｘ，Ｉｎｃ． | 微生物叢回復療法組成物を製造、処理、および梱包するための方法 |
| US10828340B2 (en) | 2015-06-09 | 2020-11-10 | Rebiotix, Inc. | Microbiota restoration therapy (MRT) compositions and methods of manufacture |
| TWI571254B (zh) * | 2016-01-08 | 2017-02-21 | 誠熱實業股份有限公司 | 放射治療用之醫療輔助裝置 |
| CN105769774A (zh) * | 2016-03-02 | 2016-07-20 | 张光泉 | 一种注射用醋酸地加瑞克冻干组合物及其制备方法 |
| US10933134B2 (en) * | 2017-03-16 | 2021-03-02 | Memorial Sloan Kettering Cancer Center | Combination therapies for treatment of cancer |
| RU2731002C1 (ru) * | 2019-10-22 | 2020-08-26 | Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) | Способ лечения рака предстательной железы |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| EP0002749B2 (en) | 1977-12-26 | 1987-08-12 | IHARA CHEMICAL INDUSTRY Co., Ltd. | Process for producing aromatic monocarboxylic acid |
| EP0593491B1 (en) | 1991-04-25 | 1996-10-23 | DEGHENGHI, Romano | Luteinizing hormone releasing hormone antagonist peptides |
| ATE200428T1 (de) | 1992-02-12 | 2001-04-15 | Daikyo Gomu Seiko Kk | Medizinisches gerät |
| SI9300468A (en) | 1992-10-14 | 1994-06-30 | Hoffmann La Roche | Injectable composition for the sustained release of biologically active compounds |
| US5506207A (en) | 1994-03-18 | 1996-04-09 | The Salk Institute For Biological Studies | GNRH antagonists XIII |
| US5595760A (en) | 1994-09-02 | 1997-01-21 | Delab | Sustained release of peptides from pharmaceutical compositions |
| US5860957A (en) | 1997-02-07 | 1999-01-19 | Sarcos, Inc. | Multipathway electronically-controlled drug delivery system |
| US5821230A (en) | 1997-04-11 | 1998-10-13 | Ferring Bv | GnRH antagonist decapeptides |
| US5925730A (en) | 1997-04-11 | 1999-07-20 | Ferring Bv | GnRH antagonists |
| FR2776520B1 (fr) | 1998-03-25 | 2000-05-05 | Sod Conseils Rech Applic | Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation |
| US20040198706A1 (en) | 2003-03-11 | 2004-10-07 | Carrara Dario Norberto R. | Methods and formulations for transdermal or transmucosal application of active agents |
| EP1404384B1 (en) * | 2001-07-11 | 2007-03-21 | SCA Hygiene Products AB | Coupling of cyclic oligosaccharides to polysaccharides |
| GB0117057D0 (en) | 2001-07-12 | 2001-09-05 | Ferring Bv | Pharmaceutical composition |
| US7098305B2 (en) * | 2001-09-06 | 2006-08-29 | Ardana Bioscience Limited | Sustained release of microcrystalline peptide suspensions |
| CN1411803A (zh) | 2002-08-29 | 2003-04-23 | 四川大学 | 制备前体脂质体的方法及其装置 |
| DK1565160T3 (da) * | 2002-09-27 | 2014-04-28 | Terna Zentaris Gmbh | Administrationsform til farmaceutisk aktive peptider med vedvarende frigivelse og en fremgangsmåde til fremstilling deraf |
| AR042815A1 (es) | 2002-12-26 | 2005-07-06 | Alza Corp | Dispositivo de suministro de agente activo que tiene miembros compuestos |
| EP1674082A1 (de) | 2004-12-22 | 2006-06-28 | Zentaris GmbH | Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel |
| WO2007130809A2 (en) | 2006-05-06 | 2007-11-15 | Volodymyr Brodskyy | An automatic injectable drug mixing device |
| EP1891964A1 (en) | 2006-08-08 | 2008-02-27 | AEterna Zentaris GmbH | Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits |
| EP1967202A1 (en) | 2007-03-05 | 2008-09-10 | AEterna Zentaris GmbH | Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity |
| IL182922A0 (en) | 2007-05-02 | 2007-09-20 | Medimop Medical Projects Ltd | Automatic liquid drug reconstitution apparatus |
| TWI539959B (zh) | 2008-02-11 | 2016-07-01 | 菲瑞茵國際中心股份有限公司 | 治療轉移階段攝護腺癌的方法 |
| ES2589322T3 (es) | 2008-02-11 | 2016-11-11 | Safety Syringes, Inc. | Jeringa con protector de seguridad de aguja y clip para evitar la liberación del protector durante un proceso de reconstitución |
| AU2010243273B2 (en) | 2009-05-01 | 2016-06-16 | Ferring B.V. | Composition for the treatment of prostate cancer |
| TW201043221A (en) | 2009-05-06 | 2010-12-16 | Ferring Int Ct Sa | Kit and method for preparation of a Degarelix solution |
| US20110039787A1 (en) | 2009-07-06 | 2011-02-17 | Ferring International Center S.A. | Compositions, kits and methods for treating benign prostate hyperplasia |
| LT2632934T (lt) | 2010-10-27 | 2017-01-10 | Ferring B.V. | Degarelikso ir jo tarpinių darinių gamybos būdas |
| EP2447276A1 (en) | 2010-10-27 | 2012-05-02 | Ferring B.V. | Process for the manufacture of Degarelix and its intermediates |
| JO3755B1 (ar) | 2011-01-26 | 2021-01-31 | Ferring Bv | تركيبات تستوستيرون |
| AU2012284200B2 (en) | 2011-07-15 | 2016-09-22 | Ferring B.V. | Method for timing a colonoscopy wherein a picosulate composition is administered |
-
2010
- 2010-04-30 AU AU2010243273A patent/AU2010243273B2/en active Active
- 2010-04-30 JP JP2012507846A patent/JP5973909B2/ja active Active
- 2010-04-30 KR KR1020117025625A patent/KR101795643B1/ko active Active
- 2010-04-30 ES ES10726197.6T patent/ES2641767T3/es active Active
- 2010-04-30 TW TW104130953A patent/TWI583391B/zh active
- 2010-04-30 NZ NZ595767A patent/NZ595767A/xx unknown
- 2010-04-30 RU RU2011142843/15A patent/RU2536245C2/ru active
- 2010-04-30 WO PCT/IB2010/001063 patent/WO2010125468A1/en not_active Ceased
- 2010-04-30 EP EP10726197.6A patent/EP2424503B1/en active Active
- 2010-04-30 AR ARP100101489A patent/AR078224A1/es not_active Application Discontinuation
- 2010-04-30 TW TW099113849A patent/TWI508734B/zh active
- 2010-04-30 CN CN2010800191738A patent/CN102421414A/zh active Pending
- 2010-04-30 CN CN201610082160.4A patent/CN105663059A/zh active Pending
- 2010-04-30 BR BRPI1010874A patent/BRPI1010874A8/pt not_active Application Discontinuation
- 2010-04-30 CA CA2759888A patent/CA2759888A1/en not_active Abandoned
- 2010-04-30 MX MX2011011431A patent/MX2011011431A/es active IP Right Grant
- 2010-04-30 US US12/771,199 patent/US8722088B2/en active Active
- 2010-05-01 SA SA110310340A patent/SA110310340B1/ar unknown
-
2011
- 2011-10-23 IL IL215772A patent/IL215772A/en active IP Right Grant
- 2011-10-27 ZA ZA2011/07879A patent/ZA201107879B/en unknown
-
2015
- 2015-03-24 JP JP2015060929A patent/JP6462447B2/ja active Active
-
2020
- 2020-07-30 JP JP2020129078A patent/JP7296922B2/ja active Active
-
2022
- 2022-03-29 JP JP2022052785A patent/JP7297116B2/ja active Active
-
2023
- 2023-04-21 JP JP2023069860A patent/JP7665674B2/ja active Active
-
2025
- 2025-04-09 JP JP2025064140A patent/JP2025106459A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR078224A1 (es) | Composicon para el tratamiento del cancer de prostata | |
| CO6160321A2 (es) | Uso de 2-6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil-4-fluoro-benzonitrilo | |
| AR081254A1 (es) | Composicion farmaceutica que comprende ave0010 e insulina glargina | |
| ECSP088974A (es) | Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3) | |
| CY1114215T1 (el) | Φαρμακευτικες συνθεσεις διαλυματος για υπο πιεση εισπνευστηρες μετρουμενης δοσης | |
| AR081439A1 (es) | Composicion para el tratamiento de la hiperplasia prostatica benigna de prostata | |
| PE20170302A1 (es) | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington | |
| AR072442A1 (es) | Metodo para la terapia del cancer, uso, kit | |
| AR095338A1 (es) | Método de tratamiento no tóxico para la abstinencia de drogas | |
| CO6150188A2 (es) | Uso de teencteplasa para tratar un ictus isquemico agudo | |
| CO6640268A2 (es) | Formas de decodificación oral de bendamustina y su uso terapéutico | |
| MX2014002171A (es) | Tratamientos de combinacion para hepatitis c. | |
| BR112012008345A2 (pt) | regime de dosagem para a administração de um anticorpo biespecífico de epcamxcd3 | |
| AR086356A1 (es) | Combinacion farmaceutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2 | |
| AR090885A1 (es) | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple | |
| AR082803A1 (es) | Metodos y formulaciones para el tratamiento de la trombosis con betrixaban y un inhibidor de la glicoproteina p | |
| CO6280574A2 (es) | Metodos para utilizar antagonistas de vasopresina con agentes de quimioterapia con antraciclina para reducir la cardiotoxicidad y/o para mejorar la supervivencia | |
| AR062659A1 (es) | Composicion de liberacion sostenida de levodopa y metodo para su uso | |
| PE20221338A1 (es) | Metodos de tratamiento del cancer de pulmon de celulas pequenas con formulaciones de lurbinectedina | |
| CL2021003034A1 (es) | Métodos de tratamiento del síndrome de sjögren utilizando un inhibidor de la tirosina quinasa de bruton | |
| EP4578461A3 (en) | Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa | |
| AR080096A1 (es) | Tratamiento combinado de cancer de pancreas con gemcitabina y masitinib | |
| BR112022000382A2 (pt) | Administração de agonista de sting e inibidores de checkpoint | |
| CL2016002318A1 (es) | Composición farmacéutica en forma de solución que comprende un portador líquido que comprende agua y entre 20% y 95% de uno o mas alcoholes y citrato de sildenafil disuelto en dicho portador líquido a una concentración de entre 7 y 125 mg/ml; métodos para obtenerla; forma de dosificación oral; forma de dosificación bucal; kits. | |
| ECSP077843A (es) | Tratamiento o prevención del prurito |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |